Tests BMS-986463 in adults with advanced ovarian, uterine, or lung cancer
Tests a new drug, BMS-986463, at rising doses in adults with advanced cancers.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Key facts
- Where
- Montreal, Toronto, and Vancouver, CanadaSee the 4 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain advanced cancers that cannot be removed by surgery or have spread. The cancers named are high-grade serous ovarian, uterine serous and non-small cell lung cancer.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Advanced cancer that cannot be removed by surgery or has spread (unresectable/metastatic carcinoma). Named cancers: high-grade serous ovarian carcinoma, uterine serous carcinoma, non-small cell lung cancer.
- Earlier treatment
- No radiation therapy in the 2 weeks before starting the study treatment.
Main reasons for not taking part
- Cancer spread to the membranes around the brain and spinal cord (leptomeningeal metastases)
- Another cancer that needs treatment now
- Another cancer in the past that was active within 2 years before treatment
- Radiation therapy within 2 weeks before starting the study treatment
Read by machine on 9 November 2026.
Where in Canada
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaTaking people
- Jewish General HospitalMontreal, CanadaTaking people
- Princess Margaret Cancer CentreToronto, CanadaTaking people
- BC Cancer - VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06476808EU 2025-523067-38-01
- Record updated
- 20 July 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.Read full original descriptionShow less
A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Inclusion: Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1; Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained; Participants must have an unresectable/metastatic carcinoma.
Exclusion: Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment; Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment; Participants must not have Leptomeningeal metastases; Other protocol-defined Inclusion/Exclusion criteria apply.